Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) enrolled in the INNOVATIONS trial,...

Full description

Saved in:
Bibliographic Details
Published in:Oncol Lett
Main Authors: Villalobos, Matthias, Czapiewski, Piotr, Reinmuth, Niels, Fischer, Jürgen R., Andreas, Stefan, Kortsik, Cornelius, Serke, Monika, Wolf, Martin, Neuser, Petra, Reuss, Alexander, Schnabel, Philipp A., Thomas, Michael
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2019
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6507446/
https://ncbi.nlm.nih.gov/pubmed/31186697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10153
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items